Bayer shares fell sharply after the company stopped a late-stage study for a blood-thinning drug early because of lack of efficacy and was told to pay $1.56…

Bayer shares fell sharply after the company stopped a late-stage study for a blood-thinning drug early because of lack of efficacy and was told to pay $1.56 billion in a lawsuit relating to its Roundup weedkiller. Bayer said late Sunday that it discontinued a Phase 3 clinical trial to test its…

#bayer #roundup #asundexian